
Joining forces for mRNA breakthrough
Global biotech Dyadic International Inc. and French bYoRNA SAS officially sealed a strategic partnership on the 26th of September aimed at advancing...

Memo Therapeutics AG raises CHF25m
The CHF25m Series C round of Schlieren-based Memo Therapeutics AG was led by Pureos Bioventures. Existing investors Swisscanto, Vesalius Biocapital,...

Alfasigma SpA set to take over Galapagos programme
Under the planned agreement, Alfasigma SpA will pay €50m upfront, milestones totaling €120m and mid-single to mid-double digit royalties on European...

ViaNautis Bio Ltd closes US$25m Series A financing
The US$25m round of cambridge-based ViaNautis Bio Ltd, founded in 2018 as SomaServe, was led 4BIO Capital, BGF (both UK), and UCB Ventures (UK, US,...

SpliceBio has made up a US $216m alliance with Spark Therapeutics
Under a globally exclusive licence option agreement with Roche AG, SpliceBio secures an upfront payment, opt-in and milestone payments up to $216m...

SOTIO Biotech licenses ADCs from Lonza subsidiary Synaffix BV
Lonza's centre of excellence, Synaffix B.V. (Amsterdam, The Netherlands) has entered a licensing agreement with immuno-oncology specialist SOTIO...

Pierre Fabre Laboratories acquires Vertical Bio
The acquisition of Vertical Bio AG for an undisclosed amount of money allows Pierre Fabre Laboratories to...